Bio­Haven hopes to soothe Chi­nese headaches with Shang­hai sub­sidiary

Cap­i­tal­iz­ing on the bur­geon­ing bio­phar­ma in­ter­est in Chi­na, neu­ro-fo­cused drug de­vel­op­er Bio­Haven $BHVN is set­ting up shop in Shang­hai with a sub­sidiary called BioShin that will be tasked with shep­herd­ing the Con­necti­cut-based com­pa­ny’s ar­se­nal of late-stage mi­graine and neu­rol­o­gy prod­ucts in mar­kets across the Asia-pa­cif­ic re­gion.

Bio­Haven, which ear­li­er this week said it had sub­mit­ted a US ap­pli­ca­tion to mar­ket a sub­lin­gual for­mu­la­tion of the ALS drug rilu­zole, is gear­ing up to re­port key da­ta from a piv­otal late-stage tri­al test­ing its acute mi­graine drug, rimegepant, be­fore the end of the year in the Unit­ed States. The com­pa­ny’s in­ter­est is Chi­na is not un­ex­pect­ed, giv­en that large swathes of the re­gion’s im­mense pop­u­la­tion suf­fer from mi­graine and oth­er cen­tral ner­vous sys­tem dis­or­ders, al­though pa­tients have not ben­e­fit­ed from the heady pace of med­ical in­no­va­tion their US coun­ter­parts have en­joyed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.